Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies

被引：2
|
作者：
Comeau, Michael R.
Mitchell, Danielle
Gottschalk, Rebecca
Misher, Lynda
Daugherty, Mollie
Parr, Lara
Pavlik, Peter
Woodruff, Brian
Fang, Hang
Aguilar, Megan
Bannink, Jeannette
Johnson, Starrla
Li, Gary
Miller, Robert E.
Bader, Robert
Zhang, Nicole
Sewell, Toddy
Dasovich, Maria
Hoyos, Gabriela H.
Blankenship, John W.
McMahan, Catherine
Bienvenue, David
Gross, Jane A.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-597
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
597
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ANTI-CD3 AND ANTI-CD2-INDUCED T-CELL ACTIVATION IN PRIMARY SJOGRENS SYNDROME
    GERLI, R
    BERTOTTO, A
    CERNETTI, C
    AGEA, E
    CRUPI, S
    ARCANGELI, C
    SPINOZZI, F
    GALANDRINI, R
    RAMBOTTI, P
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1989, 7 : S129 - S134
  • [22] TGF-β, T-cell tolerance and anti-CD3 therapy
    Bommireddy, R
    Doetschman, T
    TRENDS IN MOLECULAR MEDICINE, 2004, 10 (01) : 3 - 9
  • [23] Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
    El Khawanky, Nadia
    Hughes, Amy
    Yu, Wenbo
    Myburgh, Renier
    Matschulla, Tony
    Taromi, Sanaz
    Aumann, Konrad
    Clarson, Jade
    Vinnakota, Janaki Manoja
    Shoumariyeh, Khalid
    Miething, Cornelius
    Lopez, Angel F.
    Brown, Michael P.
    Duyster, Justus
    Hein, Lutz
    Manz, Markus G.
    Hughes, Timothy P.
    White, Deborah L.
    Yong, Agnes S. M.
    Zeiser, Robert
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [24] Bispecific anti-CD3xanti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies
    Ma, Li
    Ma, Juan
    Sun, Xin
    Liu, Honggang
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 522 - 531
  • [25] Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies
    Reed, Daniel R.
    Lum, Lawrence G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (08) : 761 - 772
  • [26] ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR REDIRECTED T CELLS FOR RELAPSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
    Ruella, M.
    Shestova, O.
    Kenderian, S.
    Barrett, D.
    Grupp, S.
    Scholler, J.
    Lacey, S.
    Kalos, M.
    June, C. H.
    Gill, S.
    CYTOTHERAPY, 2014, 16 (04) : S8 - S8
  • [27] Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
    Nadia El Khawanky
    Amy Hughes
    Wenbo Yu
    Renier Myburgh
    Tony Matschulla
    Sanaz Taromi
    Konrad Aumann
    Jade Clarson
    Janaki Manoja Vinnakota
    Khalid Shoumariyeh
    Cornelius Miething
    Angel F. Lopez
    Michael P. Brown
    Justus Duyster
    Lutz Hein
    Markus G. Manz
    Timothy P. Hughes
    Deborah L. White
    Agnes S. M. Yong
    Robert Zeiser
    Nature Communications, 12
  • [28] Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
    Watts, Justin M.
    Lin, Tara
    Wang, Eunice S.
    Mims, Alice S.
    Cull, Elizabeth H.
    Patel, Prapti A.
    Shami, Paul J.
    Walter, Roland B.
    Cogle, Christopher R.
    Chenault, Ruth A.
    Macpherson, Bret
    Chunyk, Allison Given
    McMahan, Catherine J.
    Gross, Jane A.
    Stromatt, Scott
    BLOOD, 2020, 136
  • [29] ANTI-CD3 - ANTI-IL-2 RECEPTOR (CD3,25) BISPECIFIC MONOCLONAL-ANTIBODY (BSMAB) - T-CELL IMMUNOMODULATION WITH REDUCED ACTIVATION AND TOXICITY THAN ANTI-CD3 MAB INVIVO
    MACLEAN, JA
    SU, Z
    COLVIN, RB
    WONG, JT
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A189 - A189
  • [30] In vivo secretion of anti-CD3 x anti-tumor bispecific antibodies by gene-modified cells: over a decade of T-cell engagement
    Compte, Marta
    Sanz, Laura
    Alvarez-Vallina, Luis
    MOLECULAR THERAPY, 2015, 23 (04) : 612 - 613
12345